We performed a genome-wide association study of total hip replacements, based on variants identified through whole-genome sequencing, which included 4,657 Icelandic patients and 207,514 population controls. We discovered two rare signals that strongly associate with osteoarthritis total hip replacement: a missense variant, c.1141G>C (p.Asp369His), in the COMP gene (allelic frequency = 0.026%, P = 4.0 × 10 −12 , odds ratio (OR) = 16.7) and a frameshift mutation, rs532464664 (p.Val330Glyfs*106), in the CHADL gene that associates through a recessive mode of inheritance (homozygote frequency = 0.15%, P = 4.5 × 10 −18 , OR = 7.71). On average, c.1141G>C heterozygotes and individuals homozygous for rs532464664 had their hip replacement operation 13.5 years and 4.9 years earlier than others (P = 0.0020 and P = 0.0026), respectively. We show that the full-length CHADL transcript is expressed in cartilage. Furthermore, the premature stop codon introduced by the CHADL frameshift mutation results in nonsense-mediated decay of the mutant transcripts.
Osteoarthritis is a highly heterogeneous disease or a set of disorders with a great impact on the quality of life. Osteoarthritis is a disease of the entire joint, affecting cartilage, synovium, subchondral bone, ligaments and the joint capsule 1 . Total hip replacement (THR) is a treatment for severe osteoarthritis of the hip, indicated by severe pain and reduced mobility, although radiographic changes in these subjects may vary. Genome-wide association studies (GWAS) of hip osteoarthritis have reported a number of common sequence variants, all conferring small to moderate effects [2] [3] [4] [5] [6] [7] . Here we report on a GWAS yielding two rare sequence variants that associate with end-stage hip osteoarthritis (THR).
We included 4,657 Icelanders who underwent THR because of osteoarthritis as cases and 207,514 individuals as population controls in the GWAS. The sequence variants included in the analyses were identified through whole-genome sequencing of 8,453 Icelanders and subsequently imputed into 150,656 individuals who had been chiptyped and their first-and second-degree relatives. We then tested for association between THR and these sequence variants (31.6 million variants under the multiplicative model and 19.2 million variants under the recessive model).
Under the multiplicative model, two variants met the threshold for genome-wide significance that accounts for prior probability of impact of the variants 8 (Online Methods and Supplementary Fig. 1) : a rare missense variant in the COMP gene (encoding cartilage oligomeric matrix protein) at 19p13.11 (hg38 position chr19:18,787,521, P = 3.1 × 10 −9 , OR = 10.4, allelic frequency = 0.033%) and a frameshift variant in the CHADL gene (encoding chondroadherin-like) at 22q13.2 (rs532464664, P = 1.5 × 10 −7 , OR = 1.37, allelic frequency = 3.92%). Variants at other loci did not reach genome-wide significance. Nominal association (P < 0.05) was observed for 9 of the 12 previously reported hip osteoarthritis risk loci (Supplementary Table 1) .
Because the variant in COMP was very rare in our data set, it was validated by direct genotyping. The directly typed genotypes were then used to reimpute the variant into the osteoarthritis cases and controls (Supplementary Note). This resulted in improved imputation (imputation information = 1.00 versus 0.95) and stronger association (P = 4.0 × 10 −12 , Whole-genome sequencing identifies rare genotypes in COMP and CHADL associated with high risk of hip osteoarthritis OR = 16.7, allelic frequency = 0.026%, or 1 in 1,900 persons in our study population; Table 1 and Supplementary Table 2 ).
The variant in the COMP gene is a C-to-G transversion at hg38 position chr19:18,787,521 (NM_000095.2:c.1141G>C, NP_000086.2: p.Asp369His), resulting in replacement of asparagine with histidine at amino acid position 369 of the COMP protein ( Supplementary  Fig. 2 ). The COMP protein is an important functional component of the extracellular matrix of cartilage 9 , and serum levels of the protein are an indicator of cartilage breakdown. As such, it is being evaluated as a prognostic marker for incidence of knee and hip osteoarthritis 10 . Missense mutations in COMP are known to cause two skeletal dysplasias: pseudoachondroplasia (PSACH) 11 and multiple-epiphyseal dysplasia (MED) 12 ( Supplementary Fig. 2 and Supplementary Note), conditions characterized by severe to mild short-limb dwarfism with early-onset osteoarthritis due to dysplasia under a dominant mode of inheritance. None of the c.1141G>C heterozygotes (n = 117) have been diagnosed with MED or other dysplasias, and they are of normal height ( Supplementary Fig. 3 and Supplementary Table 3) . Mann-Whitney tests for age at operation gave P = 0.0025 for homozygotes versus non-carriers, P = 0.35 for heterozygotes versus non-carriers and P = 0.0080 for homozygotes versus heterozygotes. (d) Kaplan-Meier curves for THR according to genotype at rs532464664 in CHADL. The hazard ratio for homozygotes versus the two other genotypes was 8.20 (95% CI = 5.93-11.34). (e) Age at THR by genotype at the rs532464664 variant in CHADL for the UK arcOGEN cohort. In the Icelandic samples, all individuals were chip-typed and the genotypes were imputed; in the UK samples, the genotypes were derived from direct genotyping. Mann-Whitney tests were used to estimate differences in age at operation; the P values are two-sided. Hazard ratios were calculated using the Cox proportional hazard model, adjusting for sex and year of birth. The box plots in a, c and e show the age at THR operation by genotype; the bottom and top of the boxes correspond to the 25th (Q1) and 75th (Q3) percentiles, the line inside the box is the median age, and the whiskers are located at Q1 -1.5 IQR and Q3 + 1.5 IQR, respectively (where IQR is the interquartile range = Q3 -Q1).
l e t t e r s
Their disease is indistinguishable from other primary hip osteoarthritis 13 ( Supplementary Fig. 4 and Supplementary Note). The individuals heterozygous for c.1141G>C in COMP form a genealogical cluster that spans seven generations, and we were able to track the mutation to a founder born around 1840 ( Supplementary Figs. 5 and 6) . The c.1141G>C variant was also associated with radiographic osteoarthritis without THR (P = 8.1 × 10 −20 and OR = 29.6 when THR and radiographic osteoarthritis were analyzed together; 5,109 cases and 222,460 controls). The mutation also associated with knee, spine and hand osteoarthritis, albeit with weaker effects (Supplementary Table 2 ). Furthermore, we found that c.1141G>C heterozygotes were, on average, 13.5 years younger than others at the time of hip replacement, or 54.5 years old versus 68.0 years old (P = 0.0020; Fig. 1 and Supplementary Table 4 ). Heterozygous carriers of the variant in the control group were also younger, on average, than the THR case heterozygotes (Supplementary Table 5 ). The variant is not reported in the Exome Aggregation Consortium (ExAC) Browser 14 , the Genome Aggregation Database (gnomAD) 14 or the Exome Variant Server (EVS), and it was not found in additional samples of European origin (n = 12,980) whom we directly genotyped. Thus, the variant likely represents a single mutational event that predisposes to osteoarthritis at the mild end of the COMP gene mutation spectrum and follows a dominant mode of inheritance (see the Supplementary Note for more data on the c.1141G>C (p.Asp369His) variant).
The association of the rs532464664 frameshift variant in CHADL with THR was much stronger under the recessive model than under the multiplicative model ( Supplementary Fig. 1b ), reaching P = 4.5 × 10 −18 and OR = 7.7 ( Table 1) . Furthermore, the associated risk in the multiplicative model could be fully explained by the contribution of the homozygous individuals. The frameshift variant is an 8-bp insertion, rs532464664, in the third exon of CHADL (NM_138481.1: c.988_989insGGCGCGCG, NP_612490.1:p.Val330Glyfs*106, allele frequency = 3.92%, homozygous frequency = 0.15%) that puts the protein out of frame at amino acid 330 of the 762-amino-acid fulllength protein and introduces a stop codon 106 amino acids downstream of the frameshift (Supplementary Fig. 7) . Under the recessive model, eight additional variants at the CHADL locus, all highly correlated with the frameshift mutation, associated with THR. None of these variants associated significantly after accounting for the effect of the homozygous state of the rs532464664[insGGCGCGCG] allele (Fig. 2, Supplementary Fig. 8 and Supplementary Table 6 ).
Similar to the variant in COMP, we found that the rs532464664 variant affected the age at THR: homozygous individuals were, on average, 4.9 years younger when they had their hip replacement (P = 0.0073; Fig. 1c,d and Supplementary Table 7) . Homozygous individuals in the control group were also younger than those in the THR group (Supplementary Table 5 ). We reexamined all available radiographs of the hip for 74 of the homozygous individuals and demonstrated that the disease was indistinguishable from other primary hip osteoarthritis ( Supplementary Fig. 9 and Supplementary Note).
The rs532464664 variant is in a region with very high GC content (80%) that is poorly covered by the standard Illumina TruSeq sequencing technique. This may explain why the variant is not reported in the ExAC 14 , gnomAD 14 or EVS databases ( Supplementary Fig. 10 and Supplementary Table 8) . However, because a large fraction of our sequencing data was generated with either the Illumina PCR-free TruSeq or Illumina TruSeq Nano methods that perform better than the standard TruSeq method in GC-rich regions, we were able to reliably call rs532464664 (Supplementary Fig. 11 ).
We directly genotyped the rs532464664 variant in ten different populations, four of which included THR samples (Online Methods). rs532464664 was present in all the populations we examined except Koreans, with a frequency ranging from 0.13% to 2.55% (Supplementary Table 9) .
We found five homozygous individuals who had undergone THR in UK samples (n THR = 2,711), one in Danish samples (n THR = 660), one in Norwegian samples (n THR = 138) and none in Swedish samples (n THR = 376). Because of the low frequency of homozygous individuals in these samples (0.041% to 0.065%), we lacked statistical power to assess association with THR. However, we observed, as in Iceland, a similar although non-significant (P = 0.081) trend of THR at a younger age for the homozygous UK individuals: homozygous individuals were, on average, 8 years younger when they had their hip replacement (Fig. 1e) .
We explored the mRNA expression of the CHADL gene in RNA sequencing data from white blood cells (n = 2,528), adipose tissue (n = 655) and cartilage (n = 16) and identified two types of CHADL transcript: a full-length transcript in cartilage and a shorter noncoding transcript, with its start site in exon 3 downstream of rs532464664, in adipose tissue (Supplementary Fig. 12) . In adipose tissue, rs532464664 was correlated with increased expression of the shorter transcript (P = 1.4 × 10 −23 , 54% increase in expression per allele carried) (Supplementary Fig. 13) .
We further explored the CHADL mRNA expression profile in 23 tissues by qPCR (Online Methods) and found that the highest expression of full-length CHADL was in the spinal cord and brain, followed by cartilage tissue (Supplementary Fig. 14) . Specific qPCR analysis of joint tissue samples showed the highest expression of full-length (Fig. 3a) and in cultured chondrocytes (Fig. 3b,c) . The high expression of the CHADL gene in cartilage is in line with expression of the mouse homolog, Chadl 15 . Because no carriers of rs532464664 were found among the RNAsequenced cartilage samples, we could not determine whether the premature stop codon introduced by rs532464664 induced nonsensemediated decay (NMD), a process responsible for eliminating aberrant mRNA transcripts with premature stop codons 16 . To investigate the potential NMD effect of the premature stop codon, we used an in vitro reporter system to evaluate NMD (Online Methods and Supplementary  Fig. 15 ). Similar systems have been used successfully to monitor the status of the NMD machinery in cells 17, 18 . We found that expression of the reporter protein was reduced when the gene encoding it was fused to a gene fragment harboring rs532464664 [insGGCGCGCG] in comparison to the wild-type allele, and this reduction was partially reverted with NMD inhibitors, indicating that rs532464664 induces NMD of the aberrant mRNA (Supplementary Fig. 15 ). Chadl knockdown in a mouse chondrogenic cell line (ATCD5) demonstrated that lack of Chadl enhanced differentiation of the cell line and deposition of collagen II and aggrecan. This links the protein with the formation of extracellular matrix of the cartilage and suggests that Chadl may have a negative regulatory role in cartilage.
In summary, we report a rare missense variant in COMP and a recessive frameshift mutation in CHADL that associate strongly with osteoarthritis hip replacement. Both variants confer substantial risk of THR (OR = 16.7 and 7.7, respectively). These odds ratios are substantially higher than those for the previously reported common osteoarthritis risk variants 7 , which range from 1. 
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ONLINe MetHOds
Study populations. Iceland. The information on THRs comes from a national Icelandic hip or knee arthroplasty registry 19, 20 and from Landspitali University Hospital electronic health records. The registry was generated with computer-aided search of hospital records on all patients who had undergone total joint replacements for primary osteoarthritis of the hip or knee from any of the six orthopedic clinics in Iceland during the period from 1972 up to and including 2008. A clinician reviewed all patient records in three of the six hospitals and determined that the proportion of correct diagnosis was greater than 98%. Additionally, computer-aided search of joint replacement operations was performed in the Landspitali University Hospital's electronic health records up to and including 2015. Diagnoses such as hip fracture, rheumatoid arthritis and secondary causes of osteoarthritis, such as Perthes disease, hip dysplasia and slipped epiphysiolysis, were excluded. The total knee replacements were drawn from the same registry and from the Landspitali University Hospital. Those who had ruptured their anterior crucial ligament were also excluded from the knee replacements list. Because not all patient records could be reviewed for confirmation of diagnosis, we only included patients 40 years and older at the time of hip replacement in the genome-wide association scan. However, for the analysis of age at hip replacement and the survival analysis, we also included individuals who had surgery at an earlier age. The average age, height and weight by sex of those undergoing THR and controls are shown in Supplementary Table 10 .
Patients with hand osteoarthritis were drawn from a database of 8,500 patients with hand osteoarthritis that was initiated in 1972 (ref. 21) . Participants were considered to have hand osteoarthritis if they had either definite finger osteoarthritis or definite thumb osteoarthritis, or both. Finger osteoarthritis was defined as definite bony swellings on at least one distal interphalangeal joint on each hand. Thumb osteoarthritis was defined as definite squaring and/or dislocation of the first carpometacarpal joint.
Information on radiographic hip osteoarthritis was drawn from the Landspitali University Hospital, the total joint replacement registry and the hand osteoarthritis database.
All participants gave informed consent, and the study was approved by the Data Protection Commission of Iceland and the National Bioethics Committee of Iceland.
Other populations. The Swedish samples were from the Swedish Malmö Diet and Cancer (MDC) study of men and women living in the city of Malmö in Sweden who were born between 1923 and 1945 (men) or between 1923 and 1950 (women). The Danish samples are postmenopausal women in the age range 55-86 years taking part in the Prospective Epidemiological Risk Factor (PERF) study 22 . The Norwegian samples consisted of patients from memory clinics with cognitive symptoms or dementia and controls recruited from orthopedic clinics, all enrolled in the DemGene project 23 . The Dutch study subjects were from the 'Nijmegen Biomedical Study ' (ref. 24) . The samples from the UK included individuals visiting the Leicester Royal Infirmary, Leicester, and the Royal Hallamshire Hospital, Sheffield, individuals from three primary care practices located in the same geographical area 25 26 . The samples from the United States were from subjects taking part in a study of polycystic ovary syndrome at Massachusetts General Hospital, Boston, Massachusetts, USA 27 . Only individuals of European descent were included in this study. The Iranian samples are part of the Tehran Cardiometabolic Genetic Study (TCGS) cohort 28 . The Chinese Hong Kong samples comprise two samples of different sex, the Mr OS and Ms OS studies, for individuls aged 65 years and above 29 . The Korean samples were postmenopausal women who visited the Osteoporosis Clinic of Asan Medical Center (AMC; Seoul, Republic of Korea) 30 . All participants in these studies provided informed consent, and we obtained approval from all institutional review boards to carry out the study.
Genotyping, imputation and association analysis. Genotyping and imputation methods and the association analysis method in the Icelandic samples were essentially as previously described 31 with some modifications that are described here. In short, we sequenced the whole genomes of 8,453 Icelanders using Illumina technology to a mean depth of at least 10× (median 32×) (Supplementary Fig. 16 ). Sequencing was performed using the following three different library preparation methods and sequencing instruments from Illumina: (i) the standard TruSeq DNA library preparation method; Illumina GAIIx and/or HiSeq 2000 sequencers; (ii) the TruSeq DNA PCR-free library preparation method; Illumina HiSeq 2500 sequencers; and (iii) the TruSeq Nano DNA library preparation method; Illumina HiSeq X sequencers (see the Supplementary Note for a detailed description of the sequencing methods). SNPs and indels were identified and their genotypes were called using joint calling with the Genome Analysis Toolkit HaplotypeCaller (GATK version 3.3.0) 32 . Genotype calls were improved by using information about haplotype sharing, taking advantage of the fact that all the sequenced individuals had also been chip-typed and long-range phased. The sequence variants identified in the 8,453 sequenced Icelanders were then imputed into 150,656 Icelanders who had been genotyped with various Illumina SNP chips and had their genotypes phased using long-range phasing 33, 34 . Using genealogical information, the sequence variants were imputed into 294,212 untyped relatives of the chip-typed individuals to further increase the sample size for association analysis and increase the power to detect associations. Individuals who had undergone THRs and controls were either chip-typed individuals (n affected = 3,110, n controls = 99,911) or first-or second-degree relatives of chip-typed individuals who were not chip-typed themselves (n affected = 1,547, n controls = 107,603). The number of affected males was 2,163, and the number of affected females was 2,494. Association testing for case-control analysis was performed using logistic regression, adjusting for sex, age and county. A total of 31.6 million variants were used in the association analysis under a multiplicative model. For the recessive analysis, the number of tested variants for which we had homozygotes for the minor allele was 19.2 million. All of the variants that were tested had imputation information over 0.8.
To account for relatedness and stratification within the case and control sample sets, we applied the method of genomic control 35 . The inflation factor λ g in the χ 2 statistic in each genome-wide analysis was estimated on the basis of a subset of about 300,000 common variants, and P values were adjusted by dividing the corresponding χ 2 values by this factor. For the traits reported here, the estimated inflation factors for the multiplicative (recessive) model were 1.29 (1.11) for THR, 1.16 (1.06) for total knee replacement, 1.32 (1.13) for hand osteoarthritis and 1.04 (1.00) for radiographic hip osteoarthritis without hip replacement.
We used the weighted Holm-Bonferroni method 36 to allocate the familywise error rate of 0.05 equally across three annotation-based classes of sequence variants 8 . For the multiplicative model, this yielded significance thresholds of 1.7 × 10 −6 for loss-of-function variants (including stop-gain, frameshift, and splice acceptor or donor variants; n = 9,989), 9.8 × 10 −8 for missense variants, splice-region variants and in-frame indels (n = 170,692), and 5.3 × 10 −10 for other (noncoding) variants (n = 31,421,778); the significance thresholds and number of variants tested under the recessive model were 2.5 × 10 −6 (n = 6,799), 1.3 × 10 −7 (n = 124,475) and 8.7 × 10 −10 (n = 19,083,372), respectively.
Single-variant genotyping. The c.1141G>C (g.18787521 on chr. 19) variant in COMP was genotyped using the Centaurus (Nanogen) platform 37 . The 8-bp CHADL frameshift insertion was genotyped using a PCR-based method with the primers shown in Supplementary Table 11 . An internal size standard was added to the resulting PCR products, and the fragments were separated on an Applied Biosystems model 3730 sequencer and then detected and called using in-house Allele Caller software.
RNA sequencing analyses. Preparation of poly(A) cDNA sequencing libraries.
Total RNA was isolated from PaxGene (Qiagen) blood tubes. The quality and quantity of the isolated total RNA samples was assessed using the Total RNA 6000 Nano chip for the Agilent 2100 Bioanalyzer. cDNA libraries derived from poly(A) mRNA were generated using Illumina's TruSeq RNA Sample Prep kit. Briefly, poly(A) mRNA was isolated from total RNA samples (1-4 µg of input) using hybridizaton to poly(T) beads. The poly(A) mRNA was fragmented at 94 °C, and first-strand cDNA was prepared using random hexamers and L30000-008). Forty-eight hours after transfection, luminescence was measured using the Dual-Glo Luciferase System (Promega, E220) on a Glomax Discover (Promega, GM3000). Data are presented as the luc2/hRluc-neo ratio calculated for each well. For inhibitor experiments, cells were cultured as described and then treated with 10 mM caffeine for the last 24 h before luminescence measurements or for the last 8 h with 20 µM wortmaninn.
Data availability. The Icelandic population whole-genome sequencing data have been deposited at the European Variant Archive under accession PRJEB15197. The authors declare that the data supporting the findings of this study are available within the article, its supplementary information files and on request.
